Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
38
AKBA Quote, Financials, Valuation and Earnings
Last price:
$1.40
Seasonality move
:
0.6%
Day range:
$1.33 - $1.40
52-week range:
$1.14 - $4.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.56x
P/B ratio:
11.50x
Volume:
2.2M
Avg. volume:
3.4M
1-year change:
-27.46%
Market cap:
$375M
Revenue:
$236.2M
EPS (TTM):
-$0.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
|
$46.1M | -$0.06 | -9.38% | -100% | $4.40 |
|
ARDX
Ardelyx, Inc.
|
$118M | $0.01 | 29.44% | -24.59% | $16.10 |
|
CORT
Corcept Therapeutics, Inc.
|
$254.9M | $0.33 | 18.7% | -71.78% | $65.40 |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$55.6M | $1.50 | 31.5% | -74.47% | $244.50 |
|
MNKD
MannKind Corp.
|
$99.9M | $0.03 | 36.93% | -59.34% | $7.50 |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$56.2M | -$0.78 | 72.75% | -1.74% | $140.20 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
|
$1.40 | $4.40 | $375M | -- | $0.00 | 0% | 1.56x |
|
ARDX
Ardelyx, Inc.
|
$5.99 | $16.10 | $1.5B | -- | $0.00 | 0% | 3.54x |
|
CORT
Corcept Therapeutics, Inc.
|
$33.74 | $65.40 | $3.6B | 41.24x | $0.00 | 0% | 5.31x |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$221.24 | $244.50 | $4.4B | 37.92x | $0.00 | 0% | 16.69x |
|
MNKD
MannKind Corp.
|
$2.82 | $7.50 | $868.8M | 167.86x | $0.00 | 0% | 2.53x |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$90.02 | $140.20 | $6.1B | -- | $0.00 | 0% | 30.82x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
|
86.9% | 1.030 | 50.62% | 1.43x |
|
ARDX
Ardelyx, Inc.
|
55.47% | -0.442 | 14.6% | 3.80x |
|
CORT
Corcept Therapeutics, Inc.
|
0.93% | -3.859 | 0.17% | 2.60x |
|
LGND
Ligand Pharmaceuticals, Inc.
|
30.74% | 1.421 | 12.08% | 21.18x |
|
MNKD
MannKind Corp.
|
112.08% | 0.597 | 27.12% | 1.23x |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
63.61% | 0.368 | 3.38% | 3.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
|
$44.8M | -$8.6M | -2.39% | -33.91% | -14.84% | $31.1M |
|
ARDX
Ardelyx, Inc.
|
$113.4M | $5.1M | -18.01% | -39.5% | 4.07% | $20.6M |
|
CORT
Corcept Therapeutics, Inc.
|
$199.6M | $4.5M | 14.82% | 14.97% | 2.22% | $38.4M |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$48.6M | $20M | 11.65% | 14.07% | 33.59% | $45.3M |
|
MNKD
MannKind Corp.
|
$78.3M | -$1.7M | 3.35% | -- | -1.49% | -$9.4M |
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$52.5M | -$47.1M | -61.67% | -310.34% | -82.2% | -$26.3M |
Akebia Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns AKBA or ARDX?
Ardelyx, Inc. has a net margin of -21.25% compared to Akebia Therapeutics, Inc.'s net margin of -0.33%. Akebia Therapeutics, Inc.'s return on equity of -33.91% beat Ardelyx, Inc.'s return on equity of -39.5%.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics, Inc.77.69% -$0.05 $248.9M ARDXArdelyx, Inc.90.6% -$0.00 $374.9M -
What do Analysts Say About AKBA or ARDX?
Akebia Therapeutics, Inc. has a consensus price target of $4.40, signalling upside risk potential of 214.29%. On the other hand Ardelyx, Inc. has an analysts' consensus of $16.10 which suggests that it could grow by 168.78%. Given that Akebia Therapeutics, Inc. has higher upside potential than Ardelyx, Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Ardelyx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics, Inc.4 0 0 ARDXArdelyx, Inc.10 0 0 -
Is AKBA or ARDX More Risky?
Akebia Therapeutics, Inc. has a beta of 0.390, which suggesting that the stock is 61.05% less volatile than S&P 500. In comparison Ardelyx, Inc. has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.744%.
-
Which is a Better Dividend Stock AKBA or ARDX?
Akebia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics, Inc. pays -- of its earnings as a dividend. Ardelyx, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or ARDX?
Akebia Therapeutics, Inc. quarterly revenues are $57.6M, which are smaller than Ardelyx, Inc. quarterly revenues of $125.2M. Akebia Therapeutics, Inc.'s net income of -$12.2M is lower than Ardelyx, Inc.'s net income of -$407K. Notably, Akebia Therapeutics, Inc.'s price-to-earnings ratio is -- while Ardelyx, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics, Inc. is 1.56x versus 3.54x for Ardelyx, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics, Inc.1.56x -- $57.6M -$12.2M ARDXArdelyx, Inc.3.54x -- $125.2M -$407K
-
Which has Higher Returns AKBA or CORT?
Corcept Therapeutics, Inc. has a net margin of -21.25% compared to Akebia Therapeutics, Inc.'s net margin of 11.83%. Akebia Therapeutics, Inc.'s return on equity of -33.91% beat Corcept Therapeutics, Inc.'s return on equity of 14.97%.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics, Inc.77.69% -$0.05 $248.9M CORTCorcept Therapeutics, Inc.98.74% $0.20 $653.9M -
What do Analysts Say About AKBA or CORT?
Akebia Therapeutics, Inc. has a consensus price target of $4.40, signalling upside risk potential of 214.29%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $65.40 which suggests that it could grow by 93.84%. Given that Akebia Therapeutics, Inc. has higher upside potential than Corcept Therapeutics, Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Corcept Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics, Inc.4 0 0 CORTCorcept Therapeutics, Inc.3 1 1 -
Is AKBA or CORT More Risky?
Akebia Therapeutics, Inc. has a beta of 0.390, which suggesting that the stock is 61.05% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.288, suggesting its less volatile than the S&P 500 by 71.236%.
-
Which is a Better Dividend Stock AKBA or CORT?
Akebia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or CORT?
Akebia Therapeutics, Inc. quarterly revenues are $57.6M, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $202.1M. Akebia Therapeutics, Inc.'s net income of -$12.2M is lower than Corcept Therapeutics, Inc.'s net income of $23.9M. Notably, Akebia Therapeutics, Inc.'s price-to-earnings ratio is -- while Corcept Therapeutics, Inc.'s PE ratio is 41.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics, Inc. is 1.56x versus 5.31x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics, Inc.1.56x -- $57.6M -$12.2M CORTCorcept Therapeutics, Inc.5.31x 41.24x $202.1M $23.9M
-
Which has Higher Returns AKBA or LGND?
Ligand Pharmaceuticals, Inc. has a net margin of -21.25% compared to Akebia Therapeutics, Inc.'s net margin of 75.06%. Akebia Therapeutics, Inc.'s return on equity of -33.91% beat Ligand Pharmaceuticals, Inc.'s return on equity of 14.07%.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics, Inc.77.69% -$0.05 $248.9M LGNDLigand Pharmaceuticals, Inc.81.42% $2.12 $1.5B -
What do Analysts Say About AKBA or LGND?
Akebia Therapeutics, Inc. has a consensus price target of $4.40, signalling upside risk potential of 214.29%. On the other hand Ligand Pharmaceuticals, Inc. has an analysts' consensus of $244.50 which suggests that it could grow by 10.51%. Given that Akebia Therapeutics, Inc. has higher upside potential than Ligand Pharmaceuticals, Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Ligand Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics, Inc.4 0 0 LGNDLigand Pharmaceuticals, Inc.7 0 0 -
Is AKBA or LGND More Risky?
Akebia Therapeutics, Inc. has a beta of 0.390, which suggesting that the stock is 61.05% less volatile than S&P 500. In comparison Ligand Pharmaceuticals, Inc. has a beta of 1.207, suggesting its more volatile than the S&P 500 by 20.687%.
-
Which is a Better Dividend Stock AKBA or LGND?
Akebia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics, Inc. pays -- of its earnings as a dividend. Ligand Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or LGND?
Akebia Therapeutics, Inc. quarterly revenues are $57.6M, which are smaller than Ligand Pharmaceuticals, Inc. quarterly revenues of $59.7M. Akebia Therapeutics, Inc.'s net income of -$12.2M is lower than Ligand Pharmaceuticals, Inc.'s net income of $44.8M. Notably, Akebia Therapeutics, Inc.'s price-to-earnings ratio is -- while Ligand Pharmaceuticals, Inc.'s PE ratio is 37.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics, Inc. is 1.56x versus 16.69x for Ligand Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics, Inc.1.56x -- $57.6M -$12.2M LGNDLigand Pharmaceuticals, Inc.16.69x 37.92x $59.7M $44.8M
-
Which has Higher Returns AKBA or MNKD?
MannKind Corp. has a net margin of -21.25% compared to Akebia Therapeutics, Inc.'s net margin of -14.25%. Akebia Therapeutics, Inc.'s return on equity of -33.91% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics, Inc.77.69% -$0.05 $248.9M MNKDMannKind Corp.69.95% -$0.05 $422.4M -
What do Analysts Say About AKBA or MNKD?
Akebia Therapeutics, Inc. has a consensus price target of $4.40, signalling upside risk potential of 214.29%. On the other hand MannKind Corp. has an analysts' consensus of $7.50 which suggests that it could grow by 165.96%. Given that Akebia Therapeutics, Inc. has higher upside potential than MannKind Corp., analysts believe Akebia Therapeutics, Inc. is more attractive than MannKind Corp..
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics, Inc.4 0 0 MNKDMannKind Corp.8 1 0 -
Is AKBA or MNKD More Risky?
Akebia Therapeutics, Inc. has a beta of 0.390, which suggesting that the stock is 61.05% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.834, suggesting its less volatile than the S&P 500 by 16.605%.
-
Which is a Better Dividend Stock AKBA or MNKD?
Akebia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or MNKD?
Akebia Therapeutics, Inc. quarterly revenues are $57.6M, which are smaller than MannKind Corp. quarterly revenues of $112M. Akebia Therapeutics, Inc.'s net income of -$12.2M is higher than MannKind Corp.'s net income of -$15.9M. Notably, Akebia Therapeutics, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 167.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics, Inc. is 1.56x versus 2.53x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics, Inc.1.56x -- $57.6M -$12.2M MNKDMannKind Corp.2.53x 167.86x $112M -$15.9M
-
Which has Higher Returns AKBA or RYTM?
Rhythm Pharmaceuticals, Inc. has a net margin of -21.25% compared to Akebia Therapeutics, Inc.'s net margin of -82.97%. Akebia Therapeutics, Inc.'s return on equity of -33.91% beat Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34%.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics, Inc.77.69% -$0.05 $248.9M RYTMRhythm Pharmaceuticals, Inc.91.61% -$0.73 $382.2M -
What do Analysts Say About AKBA or RYTM?
Akebia Therapeutics, Inc. has a consensus price target of $4.40, signalling upside risk potential of 214.29%. On the other hand Rhythm Pharmaceuticals, Inc. has an analysts' consensus of $140.20 which suggests that it could grow by 55.74%. Given that Akebia Therapeutics, Inc. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Rhythm Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics, Inc.4 0 0 RYTMRhythm Pharmaceuticals, Inc.11 1 0 -
Is AKBA or RYTM More Risky?
Akebia Therapeutics, Inc. has a beta of 0.390, which suggesting that the stock is 61.05% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals, Inc. has a beta of 2.058, suggesting its more volatile than the S&P 500 by 105.795%.
-
Which is a Better Dividend Stock AKBA or RYTM?
Akebia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics, Inc. pays -- of its earnings as a dividend. Rhythm Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or RYTM?
Akebia Therapeutics, Inc. quarterly revenues are $57.6M, which are larger than Rhythm Pharmaceuticals, Inc. quarterly revenues of $57.3M. Akebia Therapeutics, Inc.'s net income of -$12.2M is higher than Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M. Notably, Akebia Therapeutics, Inc.'s price-to-earnings ratio is -- while Rhythm Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics, Inc. is 1.56x versus 30.82x for Rhythm Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics, Inc.1.56x -- $57.6M -$12.2M RYTMRhythm Pharmaceuticals, Inc.30.82x -- $57.3M -$47.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Buy
52
PZZA alert for Mar 12
Papa John's International, Inc. [PZZA] is up 19.45% over the past day.
Sell
8
EHMEF alert for Mar 12
goeasy Ltd. [EHMEF] is down 17.92% over the past day.
Buy
53
NBIS alert for Mar 12
Nebius Group NV [NBIS] is up 15.9% over the past day.
